16124-69-9

Usage

Uses

Used in Pharmaceutical Industry:
4-[(4-nitrophenyl)amino]benzoic acid is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs and biologically active molecules. Its structural properties allow for the creation of compounds with potential therapeutic effects.
Used in Research and Development:
In the field of research, 4-[(4-nitrophenyl)amino]benzoic acid is used as a building block for the design and synthesis of novel chemical entities, facilitating the exploration of new drug candidates and the advancement of scientific understanding in medicinal chemistry.
Used as a Labeling Agent in Biological and Chemical Assays:
Leveraging its fluorescent properties, 4-[(4-nitrophenyl)amino]benzoic acid is used as a labeling agent in various assays, enabling the tracking and detection of biological and chemical processes, which is crucial for research and diagnostic applications.

Upstream product

• 619-42-1 4-methoxycarbonylphenyl bromide 
• 100-01-6 4-nitro-aniline 
• 150-13-0 4-amino-benzoic acid 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 600170-74-9 4-[(4-nitrophenyl)amino]-N-pyrid-3-ylbenzamide 

Relevant academic research and scientific papers

Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N -phenyl-aminobenzoates and their structure-activity relationships

Aldo-keto reductase 1C3 (AKR1C3; type 5 17β-hydroxysteroid dehydrogenase) is overexpressed in castration resistant prostate cancer (CRPC) and is implicated in the intratumoral biosynthesis of testosterone and 5α-dihydrotestosterone. Selective AKR1C3 inhibitors are required because compounds should not inhibit the highly related AKR1C1 and AKR1C2 isoforms which are involved in the inactivation of 5α-dihydrotestosterone. NSAIDs, N-phenylanthranilates in particular, are potent but nonselective AKR1C3 inhibitors. Using flufenamic acid, 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid, as lead compound, five classes of structural analogues were synthesized and evaluated for AKR1C3 inhibitory potency and selectivity. Structure-activity relationship (SAR) studies revealed that a meta-carboxylic acid group relative to the amine conferred pronounced AKR1C3 selectivity without loss of potency, while electron withdrawing groups on the phenylamino B-ring were optimal for AKR1C3 inhibition. Lead compounds did not inhibit COX-1 or COX-2 but blocked the AKR1C3 mediated production of testosterone in LNCaP-AKR1C3 cells. These compounds offer promising leads toward new therapeutics for CRPC.

DIPHENYLAMINE DERIVATIVES

The invention relates to compounds of the formula (I) in which: i and j=1; R1 is in position 3 or 4 on the phenyl ring and represents a cyano group, an alkoxy group substituted by halogen, a thioalkyl group, an alkylcarbonyl group or an alkylsulfonyl group; and R2 represents a carboxyl group, an aikoxycarbonyl group, an alkylcarbonyl group, an unsubstituted amide group or a linear or branched alkyl group substituted by a cyano, hydroxyl, carboxyl, aikoxycarbonyl or unsubstituted amide group; and also the pharmaceutically acceptable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all propor-tions.

NITROSO DERIVATIVES OF DIPHENYLAMINE

The invention relates to a compound of the formula (I) in which: - R1 represents, independently of each other, a halogen atom; an aliphatic hydrocarbon-based group optionally substituted and/or optionally interrupted by one or more oxygen or sulfur atoms; a nitro group; a cyano group; an amino group; a mono- or dialkylamino group; an alkylcarbonyl group; a carboxyl group; an alkylcarbonylamino group; an alkylsulfonyl group; - R2 represents, independently of each other, a cyano group; a hydroxyl group, an alkylcarbonyl group; a carboxyl group; an alkoxycarbonyl group; an unsubstituted amide group; or a linear or branched alkyl group substituted by a cyano, hydroxyl, carboxyl, alkoxycarbonyl or unsubstituted amide group; - i and j independently being 1 to 5, with the exclusion of the compound for which i and j = 1 and R1 = carboxyl and R2 = alkoxycarbonyl or R1 = CF3 and R2 = carboxyl, and also the pharmaceutically acceptable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all proportions.